Wellbutrin (bupropion) is not considered harmful to the liver for most people. Liver enzyme abnormalities occur in less than 1% of patients taking the medication, and when they do appear, they’re typically mild, temporary, and resolve without stopping treatment. Serious liver injury from bupropion is rare, with only a handful of cases reported in medical literature despite widespread use.
How Common Is Liver Injury From Wellbutrin?
The overall picture is reassuring. Fewer than 1 in 100 people on bupropion show any abnormality on liver blood tests, and those elevations are usually modest and symptom-free. No cases of clinically apparent liver injury surfaced during the original clinical trials for the drug.
Since Wellbutrin entered the market, only about 7 confirmed cases of significant liver inflammation (both the type that damages liver cells directly and the type that blocks bile flow) have been formally reported. For a medication prescribed to millions of people, that’s an exceptionally low signal. The liver injury that does occur tends to involve a noticeable jump in liver enzymes, sometimes accompanied by yellowing of the skin or eyes, but these cases remain rare outliers rather than a pattern most users need to worry about.
Why the Liver Is Involved at All
Your liver does most of the work breaking down bupropion. The drug is processed through several enzyme pathways in the liver, producing three main breakdown products. One pathway uses a liver enzyme called CYP2B6 to create the primary active metabolite, hydroxybupropion. Other enzymes in the liver (and to a lesser extent the intestine) produce two additional metabolites. Because the liver handles nearly all of this processing, it’s the organ most exposed to the drug and its byproducts, which is why liver function occasionally comes up as a concern.
For a healthy liver, this workload is routine. The organ has enormous metabolic capacity and handles bupropion without difficulty in the vast majority of cases.
Pre-Existing Liver Conditions Change the Picture
If you already have liver disease, the situation is different. A compromised liver can’t break down bupropion as efficiently, so the drug and its metabolites build up in the body to higher-than-normal levels. This increases the risk of side effects, including seizures, which are the most serious known risk of bupropion at high concentrations.
The FDA label addresses this directly and in tiered detail:
- Mild liver impairment: A reduced dose or less frequent dosing may be appropriate.
- Moderate to severe liver impairment: The maximum dose is capped significantly lower than the standard dose, and close monitoring for adverse effects is recommended.
- Severe cirrhosis: The FDA uses the phrase “extreme caution” and specifies the lowest possible dosing limits. Severe cirrhosis is also listed as a factor that raises seizure risk.
If you have any form of liver disease, your prescriber should be aware of it before you start bupropion. Dose adjustments are straightforward, but they need to happen from the beginning.
Is Routine Liver Testing Required?
No. The FDA label does not call for routine liver function testing in healthy patients starting Wellbutrin. This sets it apart from a few other medications (like some cholesterol drugs or certain acne treatments) where regular blood work is standard. The risk to the liver is low enough that blanket screening isn’t considered necessary.
That said, if you develop symptoms like unusual fatigue, nausea, dark urine, or yellowing of the skin while taking bupropion, those warrant a check. These symptoms are the body’s signals that the liver may be under stress, regardless of which medication you’re on.
How Wellbutrin Compares to Other Antidepressants
All antidepressants pass through the liver, and virtually all of them carry some small risk of liver effects. A large French study tracking nearly 5 million people who started antidepressants found that serious liver injury was uncommon across every class of medication examined. SSRIs as a group are often cited as having the best overall liver safety profile, but when researchers compared other antidepressant classes head-to-head against SSRIs, none showed a statistically significant increase in serious liver injury risk.
Bupropion fits comfortably within this landscape. It is not flagged as a higher-risk option for liver problems compared to commonly prescribed alternatives. Some medications that have drawn more liver-related attention over the years include duloxetine and agomelatine, though even those risks remain small in absolute terms. The standardized incidence of serious liver injury across all the antidepressant groups studied ranged from roughly 13 to 33 cases per 100,000 person-years, meaning the baseline risk for any individual is very low regardless of which antidepressant they take.
What to Watch For
The signs of drug-related liver stress are the same no matter the medication: unexplained nausea or loss of appetite, pain in the upper right side of the abdomen, unusually dark urine, pale stools, or a yellowish tint to the skin or whites of the eyes. In the rare reported cases with bupropion, liver enzyme levels rose noticeably, sometimes with jaundice. These symptoms typically appeared during active treatment rather than after stopping.
For the vast majority of people, Wellbutrin poses no meaningful threat to liver health. The combination of very low incidence rates, no requirement for routine monitoring, and a strong safety record across millions of prescriptions makes it one of the better-tolerated antidepressants on the market from a liver perspective.